Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

This study has been completed.
Information provided by (Responsible Party):
University of Miami Sylvester Comprehensive Cancer Center Identifier:
First received: March 20, 2007
Last updated: July 25, 2014
Last verified: August 2013

RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth.

PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating patients with metastatic melanoma that cannot be removed by surgery.

Condition Intervention Phase
Melanoma (Skin)
Biological: ADI-PEG-20
Other: Pharmacology Studies
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Protocol for Phase II Testing of ADI-PEG 20 in Patients With Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by University of Miami Sylvester Comprehensive Cancer Center:

Primary Outcome Measures:
  • Response Rate (Partial and Complete Response) in Patients With or Without ASS Expression Present in Tumor. [ Time Frame: Up to 16 months ] [ Designated as safety issue: No ]
    Response rate is defined as a partial response, PR, and complete response, CR, lasting for at least 30 days per RECIST criteria, v. 1.0. Complete response will be defined as disappearance of all target lesions. Partial response will be defined as at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference the baseline sum of LD

Secondary Outcome Measures:
  • Median Overall Survival [ Time Frame: Up to 16 months ] [ Designated as safety issue: No ]
    Overall survival will be estimated using the product-limit method of Kaplan & Meier.

  • Median Time to Progression [ Time Frame: Up to 16 months ] [ Designated as safety issue: No ]
    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Enrollment: 38
Study Start Date: June 2004
Study Completion Date: February 2012
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADI-PEG 20 Biological: ADI-PEG-20
There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
Other Name: Arginine Deiminase (ADI) formulated with polyethylene glycol (PEG)
Other: Pharmacology Studies
tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue

Detailed Description:



  • Determine the clinical response (complete and partial response) in patients with unresectable metastatic melanoma treated with pegylated arginine deiminase.


  • Determine the toxicity profile of this drug in these patients.
  • Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.
  • Determine the progression-free survival and overall survival of patients treated with this drug.

OUTLINE: Patients receive pegylated arginine deiminase intramuscularly once or twice a week in weeks 1-4. Courses repeat every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Blood samples are acquired at baseline and every 2 weeks thereafter for pharmacokinetic and pharmacodynamic studies.

After completion of study treatment, patients are followed every 3 months for 1 year, every 6 months for 5 years, and annually thereafter.

PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed metastatic melanoma, meeting any of the following criteria:

    • Progressive disease after chemotherapy, radiotherapy, surgery, or immunotherapy
    • No longer responding to standard therapy OR have refused standard therapy
  • Unresectable disease
  • Measurable or evaluable disease
  • No clinical ascites
  • No symptomatic pleural effusion


  • Life expectancy ≥ 12 weeks
  • Karnofsky performance status 70-100%
  • Bilirubin ≤ 3.0 mg/dL
  • Albumin ≥ 3.0 g/dL
  • Alkaline phosphatase < 5 times upper limit of normal (ULN)
  • Serum glucose > 60 mg/dL
  • Amylase < 1.5 times ULN
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 100,000/mm³
  • No New York Heart Association class III-IV heart failure
  • No serious infection requiring treatment with antibiotics
  • No known allergy to E. coli drug products (e.g., sargramostim [GM-CSF])
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use 2 forms of effective contraception


  • See Disease Characteristics
  • At least 4 weeks since prior anticancer therapy
  • At least 4 weeks since prior surgery and recovered
  • No concurrent participation in another investigational drug study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00450372

United States, Florida
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami Sylvester Comprehensive Cancer Center
Study Chair: Lynn G. Feun, MD University of Miami Sylvester Comprehensive Cancer Center
  More Information

Additional Information:
Responsible Party: University of Miami Sylvester Comprehensive Cancer Center Identifier: NCT00450372     History of Changes
Other Study ID Numbers: UMIAMI-20030698, SCCC-2003045
Study First Received: March 20, 2007
Results First Received: February 1, 2013
Last Updated: July 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Miami Sylvester Comprehensive Cancer Center:
recurrent melanoma
stage IV melanoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas processed this record on November 25, 2014